1. AODTH-003 Vedolizumab clinical and post-marketing safety experience of opportunistic infections. (17th June 2017) Authors: Ng, SC; Palo, W; Blake, A; Rana-Khan, Q; Bhayat, F Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP005 Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonists. (16th January 2018) Authors: Cohen, R; Bhayat, F; Hantsbarger, G; Blake, A; Vermeire, S Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S032 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P051 Lower incidence of herpes zoster in vedolizumab-treated vs. tofacitinib-treated patients with ulcerative colitis. (16th January 2018) Authors: Caldera, F; Lasch, K; Lissoos, T; Cao, C; Bhayat, F Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics. (25th January 2019) Authors: Cohen, R D; Bhayat, F; Blake, A; Travis, S Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S362 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P724 Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. (25th January 2019) Authors: Card, T; Ungaro, R; Bhayat, F; Blake, A; Hantsbarger, G; Travis, S Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PTH-066 Post-marketing experience of vedolizumab: pneumonia and other respiratory tract infections. (17th June 2017) Authors: Bhayat, F; Blake, A; Travis, SP Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PTH-067 Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience. (17th June 2017) Authors: Feagan, BG; Bhayat, F; Khalid, JM; Palo, W; Blake, A; Shetzline, M; Travis, SP Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PTH-068 Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series. (17th June 2017) Authors: Zerôncio, M; Blake, A; Rana-Khan, Q; Palo, W; Bhayat, F Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗